Published in Proc Natl Acad Sci U S A on March 28, 1995
Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol Disord Drug Targets (2006) 1.97
The role of the hypothalamic-pituitary-adrenal axis in neuroendocrine responses to stress. Dialogues Clin Neurosci (2006) 1.96
Molecular recognition of corticotropin-releasing factor by its G-protein-coupled receptor CRFR1. J Biol Chem (2008) 1.94
Key role of CRF in the skin stress response system. Endocr Rev (2013) 1.77
Activation of corticotropin-releasing factor receptor 2 mediates the colonic motor coping response to acute stress in rodents. Gastroenterology (2011) 1.71
Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand. Proc Natl Acad Sci U S A (2007) 1.50
Local CRH signaling promotes synaptogenesis and circuit integration of adult-born neurons. Dev Cell (2014) 1.47
Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor. Proc Natl Acad Sci U S A (1995) 1.45
Expression of urocortin peptides in canine myocardium and plasma. Vet J (2010) 1.37
Structural requirements for peptidic antagonists of the corticotropin-releasing factor receptor (CRFR): development of CRFR2beta-selective antisauvagine-30. Proc Natl Acad Sci U S A (1998) 1.23
The cardiovascular physiologic actions of urocortin II: acute effects in murine heart failure. Proc Natl Acad Sci U S A (2004) 1.22
Modulation of pancreatic islets-stress axis by hypothalamic releasing hormones and 11beta-hydroxysteroid dehydrogenase. Proc Natl Acad Sci U S A (2011) 1.20
Corticotropin-releasing hormone (CRH) requirement in Clostridium difficile toxin A-mediated intestinal inflammation. Proc Natl Acad Sci U S A (2004) 1.19
Corticotropin-releasing factor signaling and visceral response to stress. Exp Biol Med (Maywood) (2010) 1.18
Urocortin 1 microinjection into the mouse lateral septum regulates the acquisition and expression of alcohol consumption. Neuroscience (2007) 1.12
Structural basis for hormone recognition by the Human CRFR2{alpha} G protein-coupled receptor. J Biol Chem (2010) 1.08
A soluble mouse brain splice variant of type 2alpha corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity. Proc Natl Acad Sci U S A (2005) 1.08
Corticotropin-releasing factor binding protein within the ventral tegmental area is expressed in a subset of dopaminergic neurons. J Comp Neurol (2008) 1.08
Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proc Natl Acad Sci U S A (2006) 1.08
Urocortin II mediates pro-inflammatory effects in human colonocytes via corticotropin-releasing hormone receptor 2alpha. Gut (2007) 1.05
Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci U S A (2002) 1.03
Predator threat induces behavioral inhibition, pituitary-adrenal activation and changes in amygdala CRF-binding protein gene expression. Psychoneuroendocrinology (2006) 1.03
Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis. Proc Natl Acad Sci U S A (2006) 0.98
Urocortin-induced endothelium-dependent relaxation of rat coronary artery: role of nitric oxide and K+ channels. Br J Pharmacol (2002) 0.98
The highly selective CRF(2) receptor antagonist K41498 binds to presynaptic CRF(2) receptors in rat brain. Br J Pharmacol (2002) 0.98
NMR structure of the first extracellular domain of corticotropin-releasing factor receptor 1 (ECD1-CRF-R1) complexed with a high affinity agonist. J Biol Chem (2010) 0.97
cAMP signaling in skeletal muscle adaptation: hypertrophy, metabolism, and regeneration. Am J Physiol Endocrinol Metab (2012) 0.96
Acute stress modulates the histamine content of mast cells in the gastrointestinal tract through interleukin-1 and corticotropin-releasing factor release in rats. J Physiol (2003) 0.94
Cellular adaptations of dorsal raphe serotonin neurons associated with the development of active coping in response to social stress. Biol Psychiatry (2013) 0.92
Functional and protein chemical characterization of the N-terminal domain of the rat corticotropin-releasing factor receptor 1. Protein Sci (2001) 0.91
RFamide-related peptide and messenger ribonucleic acid expression in mammalian testis: association with the spermatogenic cycle. Endocrinology (2010) 0.89
A novel corticotropin-releasing factor receptor splice variant exhibits dominant negative activity: a putative link to stress-induced heart disease. FASEB J (2009) 0.89
Melanocortin-4 receptor in the medial amygdala regulates emotional stress-induced anxiety-like behaviour, anorexia and corticosterone secretion. Int J Neuropsychopharmacol (2011) 0.89
Synthesis and characterization of a photoactivatable analog of corticotropin-releasing factor for specific receptor labeling. Proc Natl Acad Sci U S A (1996) 0.88
Glucocorticoids differentially regulate the expression of CRFR1 and CRFR2α in MIN6 insulinoma cells and rodent islets. Endocrinology (2010) 0.88
Central corticotropin releasing factor and social stress. Front Neurosci (2013) 0.88
Urocortin-deficient mice display normal stress-induced anxiety behavior and autonomic control but an impaired acoustic startle response. Mol Cell Biol (2002) 0.87
Relaxation by urocortin of human saphenous veins. Br J Pharmacol (2002) 0.87
Effects of social isolation on mRNA expression for corticotrophin-releasing hormone receptors in prairie voles. Psychoneuroendocrinology (2010) 0.86
Dopamine receptor mechanisms mediate corticotropin-releasing factor-induced long-term potentiation in the rat amygdala following cocaine withdrawal. Eur J Neurosci (2010) 0.86
Region-specific roles of the corticotropin-releasing factor-urocortin system in stress. Nat Rev Neurosci (2016) 0.85
Residue 17 of sauvagine cross-links to the first transmembrane domain of corticotropin-releasing factor receptor 1 (CRFR1). J Biol Chem (2008) 0.85
Central CRF system perturbation in an Alzheimer's disease knockin mouse model. Neurobiol Aging (2012) 0.85
Mapping of the ligand-selective domain of the Xenopus laevis corticotropin-releasing factor receptor 1: implications for the ligand-binding site. Proc Natl Acad Sci U S A (1998) 0.85
Behavioral Studies and Genetic Alterations in Corticotropin-Releasing Hormone (CRH) Neurocircuitry: Insights into Human Psychiatric Disorders. Behav Sci (Basel) (2012) 0.85
Local corticotropin releasing hormone (CRH) signals to its receptor CRHR1 during postnatal development of the mouse olfactory bulb. Brain Struct Funct (2014) 0.84
Stress and addiction: contribution of the corticotropin releasing factor (CRF) system in neuroplasticity. Front Mol Neurosci (2012) 0.83
Fractal dynamics in circadian cardiac time series of corticotropin-releasing factor receptor subtype-2 deficient mice. J Math Biol (2003) 0.82
Topographical distribution of corticotropin-releasing factor type 2 receptor-like immunoreactivity in the rat dorsal raphe nucleus: co-localization with tryptophan hydroxylase. Neuroscience (2011) 0.82
Corticotrophin-releasing factor, related peptides, and receptors in the normal and inflamed gastrointestinal tract. Front Neurosci (2011) 0.81
Expression and functional characterization of membrane-integrated mammalian corticotropin releasing factor receptors 1 and 2 in Escherichia coli. PLoS One (2014) 0.81
Corticotropin-Releasing Hormone Receptor 2 Signaling Promotes Mucosal Repair Responses after Colitis. Am J Pathol (2015) 0.80
Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance. Front Neuroendocrinol (2013) 0.80
Divergent effects of corticotropin releasing hormone on endothelial cell nitric oxide synthase are associated with different expression of CRH type 1 and 2 receptors. Br J Pharmacol (2001) 0.80
Distribution of urocortins and corticotropin-releasing factor receptors in the cardiovascular system. Int J Endocrinol (2012) 0.80
Minireview: CRF and Wylie Vale: a story of 41 amino acids and a Texan with grit. Endocrinology (2012) 0.80
Central urocortin 3 and type 2 corticotropin-releasing factor receptor in the regulation of energy homeostasis: critical involvement of the ventromedial hypothalamus. Front Endocrinol (Lausanne) (2013) 0.80
Activation of phosphatidylinositol 3-kinase/protein kinase B by corticotropin-releasing factor in human monocytes. Endocrinology (2009) 0.80
Expression and regulation of corticotropin-releasing factor receptor type 2β in developing and mature mouse skeletal muscle. Mol Endocrinol (2010) 0.80
Soluble corticotropin-releasing hormone receptor 2alpha splice variant is efficiently translated but not trafficked for secretion. Endocrinology (2009) 0.80
Urocortins and CRF type 2 receptor isoforms expression in the rat stomach are regulated by endotoxin: role in the modulation of delayed gastric emptying. Am J Physiol Gastrointest Liver Physiol (2012) 0.79
Novel expression of type 1 corticotropin-releasing hormone receptor in multiple endocrine cell types in the murine anterior pituitary. Endocrinology (2008) 0.79
Anorexia nervosa: a unified neurological perspective. Int J Med Sci (2011) 0.79
Urocortin 1 inhibits rat leydig cell function. Endocrinology (2008) 0.78
CRF type 2 receptors mediate the metabolic effects of ghrelin in C2C12 cells. Obesity (Silver Spring) (2013) 0.77
Clinical perspectives of urocortin and related agents for the treatment of cardiovascular disease. Int J Endocrinol (2012) 0.77
Urocortins are present in the rat testis. Neuropeptides (2011) 0.77
Effect of dexfenfluramine on the transcriptional activation of CRF and its type 1 receptor within the paraventricular nucleus of the rat hypothalamus. Br J Pharmacol (1996) 0.77
Increased anxiety in corticotropin-releasing factor type 2 receptor-null mice requires recent acute stress exposure and is associated with dysregulated serotonergic activity in limbic brain areas. Biol Mood Anxiety Disord (2014) 0.77
Regulation of gonadotropins by corticotropin-releasing factor and urocortin. Front Endocrinol (Lausanne) (2013) 0.76
Effects of voluntary running in the female mice lateral septum on BDNF and corticotropin-releasing factor receptor 2. Int J Pept (2011) 0.76
Peripheral corticotropin-releasing factor receptor type 2 activation increases colonic blood flow through nitric oxide pathway in rats. Dig Dis Sci (2015) 0.76
An Update on CRF Mechanisms Underlying Alcohol Use Disorders and Dependence. Front Endocrinol (Lausanne) (2016) 0.75
Regulation and roles of urocortins in the vascular system. Int J Endocrinol (2012) 0.75
Regulation of corticotropin releasing hormone receptor type 1 messenger RNA level in Y-79 retinoblastoma cells: potential implications for human stress response and immune/inflammatory reaction. Mediators Inflamm (1996) 0.75
Intrathecal urocortin I in the spinal cord as a murine model of stress hormone-induced musculoskeletal and tactile hyperalgesia. Eur J Neurosci (2015) 0.75
Involvement of mTOR in Type 2 CRF Receptor Inhibition of Insulin Signaling in Muscle Cells. Mol Endocrinol (2015) 0.75
Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem (1980) 28.03
Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science (1981) 9.64
Model systems for the study of seven-transmembrane-segment receptors. Annu Rev Biochem (1991) 5.70
Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc Natl Acad Sci U S A (1995) 2.70
Expression cloning of a human corticotropin-releasing-factor receptor. Proc Natl Acad Sci U S A (1993) 2.70
Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci U S A (1994) 2.14
Identification of a seven transmembrane helix receptor for corticotropin-releasing factor and sauvagine in mammalian brain. Neuron (1993) 2.10
Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology (1993) 1.83
Site-directed mutagenesis of the cytoplasmic domains of the human beta 2-adrenergic receptor. Localization of regions involved in G protein-receptor coupling. J Biol Chem (1988) 1.76
Identification of a Gs activator region of the beta 2-adrenergic receptor that is autoregulated via protein kinase A-dependent phosphorylation. Cell (1991) 1.74
Primary structure and functional expression of mouse pituitary and human brain corticotrophin releasing factor receptors. FEBS Lett (1993) 1.48
Corticotropin-releasing factor directly mediates colonic responses to stress. Am J Physiol (1987) 1.39
New effective gonadotropin releasing hormone antagonists with minimal potency for histamine release in vitro. J Med Chem (1986) 1.15
The extracellular amino-terminal region of the parathyroid hormone (PTH)/PTH-related peptide receptor determines the binding affinity for carboxyl-terminal fragments of PTH-(1-34). Endocrinology (1994) 1.12
Expression of the mouse corticotropin-releasing hormone gene in vivo and targeted inactivation in embryonic stem cells. J Clin Invest (1994) 1.09
Corticotropin-releasing hormone in humans. Endocr Rev (1992) 1.06
Corticotropin-releasing factor receptors in rat forebrain: autoradiographic identification. Science (1984) 1.06
Reciprocal changes in corticotropin-releasing factor (CRF)-like immunoreactivity and CRF receptors in cerebral cortex of Alzheimer's disease. Nature (1986) 1.05
Local secretion of corticotropin-releasing hormone by enterochromaffin cells in human colon. Gastroenterology (1994) 1.04
Corticotropin-releasing factor binding to the anterior pituitary receptor is modulated by divalent cations and guanyl nucleotides. Endocrinology (1986) 1.04
Functional corticotropin releasing factor receptors in the primate peripheral sympathetic nervous system. Nature (1986) 1.01
Corticotropin-releasing factor immunoreactivity in human gastrointestinal tract. Lancet (1982) 0.93
Presence of immunoreactive corticotropin-releasing factor in rat testis. Endocrinology (1988) 0.90
Corticotropin-releasing factor receptors in mouse spleen: identification, autoradiographic localization, and regulation by divalent cations and guanine nucleotides. Endocrinology (1988) 0.90
Gastrointestinal motor effects of corticotropin-releasing factor in mice. Regul Pept (1990) 0.90
Central and peripheral distribution of corticotropin-releasing factor. Fed Proc (1985) 0.89
Extrapituitary effects of corticotropin-releasing factor. Horm Metab Res Suppl (1987) 0.87
Corticotropin-releasing hormone excites myenteric neurons in the guinea-pig small intestine. Eur J Pharmacol (1992) 0.87
Effect of corticotropin-releasing factor on the electrical and mechanical activities of the guinea-pig ventricular myocardium. Gen Pharmacol (1990) 0.86
Dilatory and inotropic effects of corticotropin-releasing factor (CRF) on the isolated heart. Effects on atrial natriuretic peptide (ANP) release. Horm Metab Res (1992) 0.85
Receptors and actions of corticotropin-releasing hormone in the primate pituitary gland. J Clin Endocrinol Metab (1987) 0.85
The middle portion in the second cytoplasmic loop of the thyrotropin receptor plays a crucial role in adenylate cyclase activation. Mol Endocrinol (1994) 0.84
Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess (2004) 29.45
Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science (1981) 9.64
UMLS concept indexing for production databases: a feasibility study. J Am Med Inform Assoc (2001) 9.02
Hypothalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science (1973) 7.47
Organization of heterogeneous scientific data using the EAV/CR representation. J Am Med Inform Assoc (1999) 6.97
Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: a cohort study. Lancet (2001) 6.67
Water diffusion changes in Wallerian degeneration and their dependence on white matter architecture. Neuroimage (2001) 4.48
GEM: a proposal for a more comprehensive guideline document model using XML. J Am Med Inform Assoc (2000) 4.46
Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature (1995) 4.24
Midwife managed delivery unit: a randomised controlled comparison with consultant led care. BMJ (1994) 4.23
Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs. Science (2013) 4.17
Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J Comp Neurol (2000) 4.17
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol (1999) 3.99
The melanin-concentrating hormone system of the rat brain: an immuno- and hybridization histochemical characterization. J Comp Neurol (1992) 3.53
Interleukin-1 stimulates the secretion of hypothalamic corticotropin-releasing factor. Science (1987) 3.45
Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci U S A (2001) 3.23
Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron (1998) 3.08
Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia (2012) 3.04
Paying general practitioners: shedding light on the review of health services. J R Coll Gen Pract (1989) 2.83
Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science (1984) 2.83
Coupling of hormonal stimulation and transcription via the cyclic AMP-responsive factor CREB is rate limited by nuclear entry of protein kinase A. Mol Cell Biol (1993) 2.79
beta-Endorphin and adrenocorticotropin are selected concomitantly by the pituitary gland. Science (1977) 2.68
Primary structure of major outer membrane protein II (ompA protein) of Escherichia coli K-12. Proc Natl Acad Sci U S A (1980) 2.64
Primary structure of major outer membrane protein I of Escherichia coli B/r. Proc Natl Acad Sci U S A (1979) 2.60
An economic view of high compliance as a screening objective. BMJ (1994) 2.56
The hemodynamic and adrenergic effects of perioperative dexmedetomidine infusion after vascular surgery. Anesth Analg (2000) 2.56
The future of health care in Canada. BMJ (2001) 2.53
Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment. Cell Death Dis (2013) 2.52
Are cost of injury studies useful? Inj Prev (2000) 2.50
Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol (2001) 2.50
Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour. Nature (1982) 2.44
Mirror movements in parkinsonism: evaluation of a new clinical sign. J Neurol Neurosurg Psychiatry (2005) 2.35
A randomized trial of varenicline (Chantix) for the treatment of spinocerebellar ataxia type 3. Neurology (2012) 2.34
Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature (1986) 2.29
Recruitment methods for screening programmes: trial of a new method within a regional osteoporosis study. BMJ (1992) 2.27
Lower BMI cut-off value to define obesity in Hong Kong Chinese: an analysis based on body fat assessment by bioelectrical impedance. Br J Nutr (2001) 2.25
A peripheral blood diagnostic test for acute rejection in renal transplantation. Am J Transplant (2012) 2.25
Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J Immunol Methods (2001) 2.22
Activins are expressed early in Xenopus embryogenesis and can induce axial mesoderm and anterior structures. Cell (1990) 2.22
Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab (2009) 2.19
Subthalamic deep brain stimulation at individualized frequencies for Parkinson disease. Neurology (2012) 2.18
Betaglycan binds inhibin and can mediate functional antagonism of activin signalling. Nature (2000) 2.17
Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary. Proc Natl Acad Sci U S A (1994) 2.14
Simultaneous bilateral laser in situ keratomileusis: safety and efficacy. Ophthalmology (1999) 2.13
The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine. A postmarketing assessment. Arch Pediatr Adolesc Med (1996) 2.11
Culture of enzymatically dispersed pituitary cells: functional validation of a method. Endocrinology (1972) 2.09
Rapid regression of uterine leiomyomas in response to daily administration of gonadotropin-releasing hormone antagonist. Fertil Steril (1993) 2.09
Assessing the costs of assisted reproductive techniques. Br J Obstet Gynaecol (1996) 2.07
The impact of pre-hospital thrombolytic treatment on re-infarction rates: analysis of the Myocardial Infarction National Audit Project (MINAP). Heart (2007) 2.06
Race and differences in breast cancer survival in a managed care population. J Natl Cancer Inst (1999) 2.06
Complete amino acid sequence and glycosylation sites of glycoprotein gp71A of Friend murine leukemia virus. Proc Natl Acad Sci U S A (1982) 2.06
Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. Br J Cancer (2002) 2.03
Theaflavins in black tea and catechins in green tea are equally effective antioxidants. J Nutr (2001) 2.02
DNA-dependent protein kinase stimulates an independently active, nonhomologous, end-joining apparatus. Cancer Res (2000) 1.97
Radioimmunological screening method for specific membrane proteins. Anal Biochem (1979) 1.96
The cost of cervical cancer screening provided by a women's health nurse. Aust J Public Health (1992) 1.94
Interactions between two different inhibitory systems in the human motor cortex. J Physiol (2001) 1.91
Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science (1996) 1.91
Chiropody and the QALY: a case study in assigning categories of disability and distress to patients. Health Policy (1991) 1.89
An apoptosis-inducing genotoxin differentiates heterozygotic carriers for Werner helicase mutations from wild-type and homozygous mutants. Hum Genet (1997) 1.88
Synthetic competitive antagonists of corticotropin-releasing factor: effect on ACTH secretion in the rat. Science (1984) 1.87
A force-plate actometer for quantitating rodent behaviors: illustrative data on locomotion, rotation, spatial patterning, stereotypies, and tremor. J Neurosci Methods (2001) 1.86
Chemical and biological characterization of corticotropin releasing factor. Recent Prog Horm Res (1983) 1.86
Cloning and functional expression of a rat brain corticotropin releasing factor (CRF) receptor. Endocrinology (1993) 1.83
Corticotropin releasing factor produces behavioural activation in rats. Nature (1982) 1.82
Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue. Lancet (1979) 1.81
Effectiveness of cognitive-behavioural family intervention in reducing the burden of care in carers of patients with Alzheimer's disease. Br J Psychiatry (2000) 1.81
TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene (2010) 1.81
Risk of chronic arthropathy among women after rubella vaccination. Vaccine Safety Datalink Team. JAMA (1997) 1.78
Primary structure of corticotropin-releasing factor from ovine hypothalamus. Proc Natl Acad Sci U S A (1981) 1.78
Corticotropin releasing factor decreases postburst hyperpolarizations and excites hippocampal neurons. Science (1983) 1.77
MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink project. The Vaccine Safety Datalink Team. Pediatrics (1997) 1.77
Low serum cholesterol and mortality. Which is the cause and which is the effect? Circulation (1995) 1.73
Complications of laparoscopic procedures after concentrated training in urological laparoscopy. J Urol (2001) 1.71
Somatostatin. Recent Prog Horm Res (1975) 1.67
Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum Gene Ther (1999) 1.67
Preliminary observations on the effect of synthetic thyrotropin releasing factor on plasma thyrotropin levels in man. J Clin Endocrinol Metab (1970) 1.67
Dextromethorphan decreases the excitability of the human motor cortex. Neurology (1998) 1.66
Regulatory peptides of the hypothalamus. Annu Rev Physiol (1977) 1.64
Modulation of stress-induced ACTH release by corticotropin-releasing factor, catecholamines and vasopressin. Nature (1983) 1.64
Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production. Bioorg Med Chem Lett (1999) 1.62
Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. Curr Med Res Opin (2009) 1.62
Differential regulation of corticotropin-releasing factor mRNA in rat brain regions by glucocorticoids and stress. J Neurosci (1991) 1.62
A clone-array pooled shotgun strategy for sequencing large genomes. Genome Res (2001) 1.60
Involvement of the human pedunculopontine nucleus region in voluntary movements. Neurology (2010) 1.60
Somatotroph hyperplasia. Successful treatment of acromegaly by removal of a pancreatic islet tumor secreting a growth hormone-releasing factor. J Clin Invest (1982) 1.60
Involvement of the human subthalamic nucleus in movement preparation. Neurology (2003) 1.59
Transcranial magnetic stimulation for the treatment of seizures: a controlled study. Neurology (2002) 1.59
Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism. Endocrinology (1982) 1.58
Intracellular Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in buccal epithelial cells collected from human subjects. Infect Immun (2001) 1.58
Characterization of rat hypothalamic corticotropin-releasing factor. Proc Natl Acad Sci U S A (1983) 1.58
"Medical oophorectomy" using a long-acting GNRH agonist--a possible new approach to the treatment of endometriosis. J Clin Endocrinol Metab (1982) 1.57